• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性乳腺癌中的双阳性?基底细胞角蛋白在乳腺癌中的表达有何意义?

Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?

作者信息

Majumder Anusree, Jagani Rajat, Basu Atoshi

机构信息

Graded Specialist (Pathology), Command Hospital (Southern Command), Pune 411040, India.

Commanding Officer, Armed Forces Transfusion Centre, Delhi 110010, India.

出版信息

Med J Armed Forces India. 2020 Jan;76(1):63-70. doi: 10.1016/j.mjafi.2018.10.002. Epub 2019 Feb 26.

DOI:10.1016/j.mjafi.2018.10.002
PMID:32020971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6994750/
Abstract

BACKGROUND

Basal-like breast cancer has an unfavorable prognosis. Immunohistochemically, they are predominantly estrogen receptor (ER), progesterone receptor (PR) and CerbB2 receptor (HER2)-negative, show expression of Cytokeratins (CKs) 5/6, CK14, CK 17 and P-cadherin and are associated with germline BRCA1 mutations. Immunohistochemistry (IHC) is an easily available and relatively inexpensive technique that can detect this cancer subtype, and patients can benefit from aggressive management protocols. The aim of this study was to evaluate the expression of CK 5/6 and CK14 in breast cancer and its correlation with age, tumor grade, tumor size, histomorphological pattern, nodal status, ER, PR, HER2/neu, and Ki-67 index.

METHODS

Fifty treatment-naїve patients of breast carcinoma who underwent surgery constituted the study group. No core cut biopsy specimens were considered. Histopathological examination along with IHC was performed for CK5/6, CK14, ER, PR, HER2/neu, and Ki-67. Comparison between the expression of CK5/6 and CK14 with age, tumor size, tumor grade, histological subtype, nodal status, ER, PR, HER2/neu, and Ki-67 expression was performed using SPSS 20 version software.

RESULTS

Twenty-six percent of cases showed expression of CK5/6 and CK14. CK5/6 and CK14 expression correlated strongly with ER/PR negativity, young age, and Ki-67 proliferative index greater than 15%. No significant association with HER2/neu negativity was demonstrated. Contrasting results were obtained between CK5/6 and CK14 expression with respect to tumor grade and lymph node status.

CONCLUSION

IHC can be used to identify patients with basal phenotype breast cancer with good sensitivity and specificity, and such patients can benefit from aggressive management.

摘要

背景

基底样乳腺癌预后不良。免疫组化显示,它们主要为雌激素受体(ER)、孕激素受体(PR)和CerbB2受体(HER2)阴性,表达细胞角蛋白(CKs)5/6、CK14、CK17和P-钙黏蛋白,且与种系BRCA1突变相关。免疫组化(IHC)是一种易于获得且相对廉价的技术,可检测这种癌症亚型,患者可从积极的治疗方案中获益。本研究的目的是评估CK5/6和CK14在乳腺癌中的表达及其与年龄、肿瘤分级、肿瘤大小、组织形态学模式、淋巴结状态、ER、PR、HER2/neu和Ki-67指数的相关性。

方法

50例未经治疗且接受手术的乳腺癌患者组成研究组。未纳入粗针穿刺活检标本。对CK5/6、CK14、ER、PR、HER2/neu和Ki-67进行组织病理学检查及免疫组化。使用SPSS 20版软件对CK5/6和CK14的表达与年龄、肿瘤大小、肿瘤分级、组织学亚型、淋巴结状态、ER、PR、HER2/neu和Ki-67表达进行比较。

结果

26%的病例显示CK5/6和CK14表达。CK5/6和CK14表达与ER/PR阴性、年轻以及Ki-67增殖指数大于15%密切相关。未显示与HER2/neu阴性有显著关联。CK5/6和CK14在肿瘤分级和淋巴结状态方面的表达结果相反。

结论

免疫组化可用于以良好的敏感性和特异性识别基底型乳腺癌患者,此类患者可从积极治疗中获益。

相似文献

1
Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?三阴性乳腺癌中的双阳性?基底细胞角蛋白在乳腺癌中的表达有何意义?
Med J Armed Forces India. 2020 Jan;76(1):63-70. doi: 10.1016/j.mjafi.2018.10.002. Epub 2019 Feb 26.
2
ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases.早期和晚期复发性乳腺癌中的雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)、Ki-67和细胞角蛋白5(CK5)——转移灶中CK5表达降低
Breast Cancer (Auckl). 2013;7:23-34. doi: 10.4137/BCBCR.S10701. Epub 2013 Feb 13.
3
Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.从三阴性乳腺癌和 35 岁以下女性的组织微阵列中,通过差异标记物表达推断乳腺癌的基底上皮表型。
Breast J. 2012 Sep;18(5):399-405. doi: 10.1111/j.1524-4741.2012.01279.x. Epub 2012 Aug 10.
4
Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17.浸润性小叶癌不表达基底细胞角蛋白标志物CK5/6、CK14和CK17。
Breast Cancer (Auckl). 2010 Oct 21;4:49-55. doi: 10.4137/BCBCR.S5037.
5
Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.基底和腔面细胞角蛋白在乳腺癌中的表达及其与临床病理预后变量的相关性。
Indian J Med Sci. 2009 Apr;63(4):152-62.
6
Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.免疫组织化学鉴定浸润性乳腺癌的分子亚型:来自印度北部的一项研究。
APMIS. 2012 Dec;120(12):1008-19. doi: 10.1111/j.1600-0463.2012.02933.x. Epub 2012 Jul 26.
7
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.使用组合生物标志物对三阴性乳腺癌患者的预后进行分层
PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.
8
Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.细胞块有助于对乳腺癌中基底细胞角蛋白(CK5/6)和腔上皮细胞角蛋白(CK8/18)以及平滑肌肌动蛋白(SMA)的表达进行可靠评估。
Cytopathology. 2010 Aug;21(4):259-66. doi: 10.1111/j.1365-2303.2009.00713.x. Epub 2009 Oct 15.
9
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.猫乳腺基底样腺癌:一种具有基底样亚型的人类三阴性乳腺癌(TNBC)的潜在模型。
BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.
10
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.基底细胞角蛋白和表皮生长因子受体的表达与三阴性乳腺癌女性的 BRCA1 突变状态无关。
Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.

引用本文的文献

1
Cytokeratin expression in breast cancer: from mechanisms, progression, diagnosis, and prognosis to therapeutic implications.细胞角蛋白在乳腺癌中的表达:从机制、进展、诊断、预后到治疗意义
Mol Cell Oncol. 2025 Jul 1;12(1):2526230. doi: 10.1080/23723556.2025.2526230. eCollection 2025.
2
Programmed death ligand-1 protein expression difference in basal like and non-basal like triple negative breast cancer and its association with disease free survival and overall survival: A systematic review.基底样和非基底样三阴性乳腺癌中程序性死亡配体-1蛋白表达差异及其与无病生存期和总生存期的关联:一项系统评价
Oncol Rev. 2021 Sep 28;15(2):533. doi: 10.4081/oncol.2021.533. eCollection 2021 Sep 21.

本文引用的文献

1
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.三阴性乳腺癌中的胚系突变状态、病理完全缓解和无病生存:GeparSixto 随机临床试验的二次分析。
JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.
2
Ki-67 evaluation in breast cancer: The daily diagnostic practice.乳腺癌中Ki-67的评估:日常诊断实践
Indian J Pathol Microbiol. 2017 Apr-Jun;60(2):177-184. doi: 10.4103/IJPM.IJPM_732_15.
3
Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.乳腺癌分子分类的免疫组化替代指标:2015年更新
Arch Pathol Lab Med. 2016 Aug;140(8):806-14. doi: 10.5858/arpa.2015-0133-RA.
4
Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.对5931名中国乳腺癌女性的大型队列中BRCA1和BRCA2种系突变的综合分析。
Breast Cancer Res Treat. 2016 Aug;158(3):455-62. doi: 10.1007/s10549-016-3902-0. Epub 2016 Jul 8.
5
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.三阴性乳腺癌分子亚型的细化:对新辅助化疗选择的影响
PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
6
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.使用组合生物标志物对三阴性乳腺癌患者的预后进行分层
PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.
7
Clinical implications of molecular heterogeneity in triple negative breast cancer.三阴性乳腺癌分子异质性的临床意义
Breast. 2015 Nov;24 Suppl 2(0 2):S36-40. doi: 10.1016/j.breast.2015.07.009. Epub 2015 Aug 5.
8
St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.2015年圣加仑/维也纳:共识讨论简要总结
Breast Care (Basel). 2015 Apr;10(2):124-30. doi: 10.1159/000430488.
9
Defining breast cancer intrinsic subtypes by quantitative receptor expression.通过定量受体表达定义乳腺癌内在亚型。
Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23.
10
p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.p53状态可识别出对辅助化疗无反应的三阴性乳腺癌患者。
Breast. 2015 Jun;24(3):294-7. doi: 10.1016/j.breast.2015.01.007. Epub 2015 Feb 16.